PL2010563T3 - Sekwencja syntetycznego MECP2 do białkowej terapii substytucyjnej - Google Patents

Sekwencja syntetycznego MECP2 do białkowej terapii substytucyjnej

Info

Publication number
PL2010563T3
PL2010563T3 PL06724141T PL06724141T PL2010563T3 PL 2010563 T3 PL2010563 T3 PL 2010563T3 PL 06724141 T PL06724141 T PL 06724141T PL 06724141 T PL06724141 T PL 06724141T PL 2010563 T3 PL2010563 T3 PL 2010563T3
Authority
PL
Poland
Prior art keywords
protein
proteins
nucleic acid
relates
substitution therapy
Prior art date
Application number
PL06724141T
Other languages
English (en)
Inventor
Franco Antonio Laccone
Original Assignee
Georg August Univ Goettingen Stiftung Oeffentlichen Rechts
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Georg August Univ Goettingen Stiftung Oeffentlichen Rechts filed Critical Georg August Univ Goettingen Stiftung Oeffentlichen Rechts
Publication of PL2010563T3 publication Critical patent/PL2010563T3/pl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4702—Regulators; Modulating activity
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Public Health (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
PL06724141T 2006-04-07 2006-04-07 Sekwencja syntetycznego MECP2 do białkowej terapii substytucyjnej PL2010563T3 (pl)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
PCT/EP2006/003203 WO2007115578A1 (en) 2006-04-07 2006-04-07 Synthetic mecp2 sequence for protein substitution therapy
EP06724141A EP2010563B1 (en) 2006-04-07 2006-04-07 Synthetic mecp2 sequence for protein substitution therapy

Publications (1)

Publication Number Publication Date
PL2010563T3 true PL2010563T3 (pl) 2011-11-30

Family

ID=36589309

Family Applications (1)

Application Number Title Priority Date Filing Date
PL06724141T PL2010563T3 (pl) 2006-04-07 2006-04-07 Sekwencja syntetycznego MECP2 do białkowej terapii substytucyjnej

Country Status (15)

Country Link
US (1) US8226930B2 (pl)
EP (1) EP2010563B1 (pl)
JP (1) JP5102283B2 (pl)
CN (1) CN101415726B (pl)
AT (1) ATE500265T1 (pl)
AU (1) AU2006341726B2 (pl)
CA (1) CA2647125C (pl)
DE (1) DE602006020501D1 (pl)
DK (1) DK2010563T3 (pl)
ES (1) ES2362195T3 (pl)
HR (1) HRP20110386T1 (pl)
IL (1) IL194274A (pl)
PL (1) PL2010563T3 (pl)
SI (1) SI2010563T1 (pl)
WO (1) WO2007115578A1 (pl)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1398191B1 (it) * 2010-02-17 2013-02-14 Ist Superiore Sanita Uso di tossine che attivano le rho gtpasi per il trattamento e/o la prevenzione della sintomatologia associata alla sindrome di rett (rtt).
US9920317B2 (en) 2010-11-12 2018-03-20 The General Hospital Corporation Polycomb-associated non-coding RNAs
DK2638163T3 (en) 2010-11-12 2017-07-24 Massachusetts Gen Hospital POLYCOMB-ASSOCIATED NON-CODING RNAs
JP2015518712A (ja) 2012-05-16 2015-07-06 ラナ セラピューティクス インコーポレイテッド Ｍｅｃｐ２発現を調節するための組成物及び方法
WO2013173638A1 (en) 2012-05-16 2013-11-21 Rana Therapeutics, Inc. Compositions and methods for modulating smn gene family expression
JP2015518713A (ja) 2012-05-16 2015-07-06 ラナ セラピューティクス インコーポレイテッド Ｕｔｒｎ発現を調節するための組成物及び方法
EP2850188A4 (en) 2012-05-16 2016-01-20 Rana Therapeutics Inc COMPOSITIONS AND METHOD FOR MODULATING THE EXPRESSION OF THE HEMOGLOBIN GENE FAMILIES
CN104583401A (zh) 2012-05-16 2015-04-29 Rana医疗有限公司 用于调节atp2a2表达的组合物和方法
US10837014B2 (en) 2012-05-16 2020-11-17 Translate Bio Ma, Inc. Compositions and methods for modulating SMN gene family expression
WO2014130408A1 (en) * 2013-02-20 2014-08-28 The Research Foundation For The State University Of New York Regulators of rab5 activity
US10858650B2 (en) 2014-10-30 2020-12-08 The General Hospital Corporation Methods for modulating ATRX-dependent gene repression
WO2016149455A2 (en) 2015-03-17 2016-09-22 The General Hospital Corporation The rna interactome of polycomb repressive complex 1 (prc1)
TWI601821B (zh) * 2016-04-15 2017-10-11 中央研究院 治療神經發展性疾病
BR112018077225A2 (pt) * 2016-06-28 2019-04-09 Alma Mater Studiorum - Università di Bologna proteínas de fusão tatk-cdkl5, composições, formulações e uso das mesmas
CA3057425A1 (en) * 2017-03-24 2018-09-27 The University Court Of The University Of Edinburgh Mecp2 based therapy
WO2019079462A1 (en) * 2017-10-17 2019-04-25 President And Fellows Of Harvard College TRANSCRIPTION MODULATION SYSTEMS BASED ON CAS9
KR102052097B1 (ko) * 2017-11-30 2019-12-05 한국과학기술연구원 Mecp2 단백질 또는 이를 암호화하는 폴리뉴클레오티드를 포함하는 퇴행성 뇌질환 예방 또는 치료용 조성물
US20220202960A1 (en) * 2019-04-24 2022-06-30 The Trustees Of The University Of Pennsylvania Compositions useful in treatment of rett syndrome
WO2023235648A1 (en) * 2022-06-03 2023-12-07 The Regents Of The University Of California Nuclear Delivery and Transcriptional Repression with a Cell-penetrant MeCP2
CN119971036A (zh) * 2023-11-13 2025-05-13 中国科学院分子细胞科学卓越创新中心 核糖核酸酶RNase H修复神经元树突生长缺陷的应用和方法

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2364690A1 (en) 1999-02-28 2000-10-19 Washington University Novel transduction molecules and methods for using same
US6709817B1 (en) * 1999-09-07 2004-03-23 Baylor College Of Medicine Method of screening Rett syndrome by detecting a mutation in MECP2
WO2002085948A1 (en) * 2001-04-20 2002-10-31 Man-Wook Hur Repressors for hiv transcription and methods thereof
WO2005078099A1 (en) * 2004-02-17 2005-08-25 The Hospital For Sick Children Mecp2e1 gene

Also Published As

Publication number Publication date
JP5102283B2 (ja) 2012-12-19
AU2006341726B2 (en) 2012-09-20
HK1121468A1 (en) 2009-04-24
JP2009532045A (ja) 2009-09-10
SI2010563T1 (sl) 2011-07-29
WO2007115578A8 (en) 2008-10-30
US20090233856A1 (en) 2009-09-17
US8226930B2 (en) 2012-07-24
EP2010563A1 (en) 2009-01-07
CA2647125C (en) 2015-02-03
CN101415726A (zh) 2009-04-22
ATE500265T1 (de) 2011-03-15
CN101415726B (zh) 2013-07-31
DK2010563T3 (da) 2011-05-23
ES2362195T3 (es) 2011-06-29
DE602006020501D1 (de) 2011-04-14
AU2006341726A1 (en) 2007-10-18
CA2647125A1 (en) 2007-10-18
EP2010563B1 (en) 2011-03-02
IL194274A (en) 2011-07-31
WO2007115578A1 (en) 2007-10-18
HRP20110386T1 (hr) 2011-08-31

Similar Documents

Publication Publication Date Title
SI2010563T1 (sl) Sintetična MeCP2 sekvenca za proteinsko nadomestno terapijo
MX2009012650A (es) Secuencias de aminoacido dirigidas contra rank-l y polipeptidos que comprenden lo mismo para el tratamiento de enfermedades y trastornos de huesos.
PH12012502272A1 (en) Biological materials related to her3
ZA202002094B (en) Trispecific proteins and methods of use
WO2007104529A3 (en) Amino acid sequences directed against il-6 and polypeptides comprising the same for the treatment of diseases and disorders associated with il-6-mediated signalling
MX2010005783A (es) Secuencias de aminoacidos dirigidas contra citoquinas heterodimericas y/o sus receptores y polipeptidos que comprenden las mismas.
IN2012DN02981A (pl)
CA2818990A1 (en) Designed repeat proteins binding to serum albumin
BR112019005587A2 (pt) proteínas de ligação recombinantes e sua utilização
WO2010115998A3 (en) Improved amino acid sequences directed against il-6r and polypeptides comprising the same for the treatment of il-6r related diseases and disorders
MX359953B (es) Ácido nucleico que comprende o que codifica un tallo-rizo de histona y una secuencia poli (a) o una señal de poliadenilación para incrementar la expresión de una proteína terapéutica codificada.
BR112016002753A2 (pt) anticorpos contra o inibidor-1 de ativador de plasminogênio (pai-1) e usos dos mesmos
MX2009003729A (es) Copuestos antagonistas de acido ribonucleico para la modulacion de proproteina convertasa subtilisina/kexina tipo 9a.
WO2015024667A8 (en) Method for increasing expression of rna-encoded proteins
MY177065A (en) 4-1bb binding molecules
MX2022013520A (es) Polipeptidos que se enlazan a cxcr2.
WO2011036442A3 (en) Thrombin c- terminal polypeptides and uses thereof for treating inflammation coagulation disorders
EP3747457A3 (en) Factor 1 protein, factor 2 protein and inhibitors thereof for use in treating or preventing diseases
MX2009004243A (es) Nuevas proteinas h5, moleculas de acido nucleico y vectores que las codifican y su uso medicinal.
WO2010115995A3 (en) Improved amino acid sequences directed against il-6r and polypeptides comprising the same for the treatment of il-6r related diseases and disorders
UA100127C2 (ru) Пептид cdh3 и лекарственное средство, содержащее его
WO2009047513A3 (en) Antagonists of kisspeptin and uses thereof
WO2007145589A8 (en) Peptides that are capable of binding to amyloid-beta peptide.
WO2010103515A3 (en) Compositions and methods for prevention and treatment of neurodegenerative diseases
WO2010011994A3 (en) Polypeptides and uses thereof